GB9421223D0 - Tissue imaging in gene therapy - Google Patents

Tissue imaging in gene therapy

Info

Publication number
GB9421223D0
GB9421223D0 GB9421223A GB9421223A GB9421223D0 GB 9421223 D0 GB9421223 D0 GB 9421223D0 GB 9421223 A GB9421223 A GB 9421223A GB 9421223 A GB9421223 A GB 9421223A GB 9421223 D0 GB9421223 D0 GB 9421223D0
Authority
GB
United Kingdom
Prior art keywords
gene therapy
tissue imaging
imaging
tissue
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9421223A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Priority to GB9421223A priority Critical patent/GB9421223D0/en
Publication of GB9421223D0 publication Critical patent/GB9421223D0/en
Priority to JP8513558A priority patent/JPH10510046A/en
Priority to PCT/CA1995/000593 priority patent/WO1996012508A2/en
Priority to CA002202891A priority patent/CA2202891A1/en
Priority to EP95934027A priority patent/EP0784489A2/en
Priority to AU36486/95A priority patent/AU715811B2/en
Priority to US09/855,176 priority patent/US20020025296A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9421223A 1994-10-21 1994-10-21 Tissue imaging in gene therapy Pending GB9421223D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB9421223A GB9421223D0 (en) 1994-10-21 1994-10-21 Tissue imaging in gene therapy
JP8513558A JPH10510046A (en) 1994-10-21 1995-10-20 Use of nucleoside analog compositions for tissue imaging and therapy and gene transfection
PCT/CA1995/000593 WO1996012508A2 (en) 1994-10-21 1995-10-20 Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy
CA002202891A CA2202891A1 (en) 1994-10-21 1995-10-20 Composition use of nucleoside analogues and gene transfection for tissue imaging and thereapy
EP95934027A EP0784489A2 (en) 1994-10-21 1995-10-20 Composition use of nucleoside analogues and gene transfection for tissue imaging and therapy
AU36486/95A AU715811B2 (en) 1994-10-21 1995-10-20 Composition use of nucleoside analogues and gene transfection for tissue imaging and therapy
US09/855,176 US20020025296A1 (en) 1994-10-21 2001-05-14 Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9421223A GB9421223D0 (en) 1994-10-21 1994-10-21 Tissue imaging in gene therapy

Publications (1)

Publication Number Publication Date
GB9421223D0 true GB9421223D0 (en) 1994-12-07

Family

ID=10763176

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9421223A Pending GB9421223D0 (en) 1994-10-21 1994-10-21 Tissue imaging in gene therapy

Country Status (6)

Country Link
EP (1) EP0784489A2 (en)
JP (1) JPH10510046A (en)
AU (1) AU715811B2 (en)
CA (1) CA2202891A1 (en)
GB (1) GB9421223D0 (en)
WO (1) WO1996012508A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1160499A (en) * 1997-08-22 1999-03-02 Hiroshi Maeda Antitumor agent
WO2000025830A2 (en) * 1998-11-03 2000-05-11 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Biomimetic elements containing iodine and/or tellurium, the production thereof and their use
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes

Also Published As

Publication number Publication date
AU3648695A (en) 1996-05-15
WO1996012508A3 (en) 1996-07-11
JPH10510046A (en) 1998-09-29
AU715811B2 (en) 2000-02-10
CA2202891A1 (en) 1996-05-02
WO1996012508A2 (en) 1996-05-02
EP0784489A2 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
EP0789592A4 (en) Ocular gene therapy
PL318760A1 (en) Spiroazabicyclo compounds useful in medical treatment
IL128850A0 (en) Medical treatment
IL125756A (en) Catheter for use in surgery
ZA959616B (en) Facial tissue carpack
IL113399A0 (en) Human bone stimulating factor
GB2293651B (en) Medical untrasound imaging
GB9414157D0 (en) Medical use
GB9419021D0 (en) Therapeutic protein
GB9421223D0 (en) Tissue imaging in gene therapy
GB2303303B (en) Medical treatment
GB9521725D0 (en) Medical treatment
GB9812550D0 (en) Tumour therapy and imaging
ZA953237B (en) Medical treatment
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
GB9613629D0 (en) Reg gene expression in cancer tissue
GB9526264D0 (en) Medical treatment
IL120282A0 (en) Diagnostic imaging in radiotherapeutic treatment
ZA951421B (en) Medical treatment
GB9425773D0 (en) Medical treatment
GB9425164D0 (en) Medical treatment
GB9424728D0 (en) Medical treatment
GB9421398D0 (en) Medical treatment
GB9418696D0 (en) Gene therapy
GB9710544D0 (en) Medical treatment